BOTHELL, Wash., Oct. 22 Cardiac ScienceCorporation (Nasdaq: CSCX), a global leader in advanced cardiac monitoring anddefibrillation products, announced today it has completed its pilot programand has begun full shipments of its new "crash cart" defibrillator as part ofan existing agreement with GE Healthcare (GE).
(Logo: http://www.newscom.com/cgi-bin/prnh/20050913/SFTU139LOGO )
The crash cart defibrillator-monitor is designed specifically for use bymedical professionals to respond to cardiac emergencies in hospital settings.The new defibrillator will be manufactured by Cardiac Science and soldexclusively by GE to hospitals in the United States and Canada as the CardiacScience Powerheart(R) ECD, and to customers outside North America as the GEResponder(TM)2000. GE will be featuring the product at the upcoming AmericanHeart Association (AHA) and MEDICA trade shows in November.
"The new defibrillator-monitor meets the demanding requirements forhospital use, and demonstrates our continuing efforts to broaden our productsand services. We believe this crash cart is a compelling offering for theestimated $300 million worldwide hospital defibrillator-monitor market," saidJohn Hinson, Cardiac Science's Chief Executive Officer. "Our partnership withGE will give us the reach and scope to effectively penetrate that market, andcontribute to our goal of saving more lives. If the initial indications are ameasure of market acceptance, we believe this product will very successful forboth companies."
The defibrillators are currently available outside of North America, andare expected to be available within the U.S. and Canada during the firstquarter of 2008.
About the new defibrillator-monitor
The new defibrillator-monitor is a lightweight, rugged and portable devicedesigned for use by professionals in medically-supervised environments torespond to cardiac emergencies. Similar to Cardiac Science's line of portableAEDs, the new device is extremely easy to use, while still incorporatingadvanced resuscitation and pacing therapies for use by the trained medicalprofessional.
The new defibrillator-monitor incorporates Cardiac Science's patentedSTAR(R) biphasic escalating shock energy technology which automaticallyadjusts the magnitude of the defibrillation shock based upon each patient'sunique body type. It also employs Cardiac Science's patented RHYTHMx(R)software, which provides heart rhythm analysis and shock advice to effectivelyaddress life-threatening arrhythmias.
About Cardiac Science Corporation
Cardiac Science is truly at the heart of saving lives. The Companydevelops, manufactures, and markets a family of advanced diagnostic andtherapeutic cardiology devices and systems, including AEDs,electrocardiographs, stress test systems, Holter monitoring systems, hospitaldefibrillators, cardiac rehabilitation telemetry systems, patient monitor -defibrillators and cardiology data management systems. Cardiac Science alsosells a variety of related products and consumables, and provides acomprehensive portfolio of training, maintenance and support services. TheCompany is the successor to various entities that have owned and operatedcardiology-related businesses that sold products under the trusted brand namesBurdick(R), Powerheart(R), and Quinton(R). Cardiac Science is headquartered inBothell, WA, and also has operations in Lake Forest, California; Deerfield,Wisconsin; Shanghai, China and Manchester, United Kingdom.
Forward Looking Statements
This press release contains forward-looking statements, including, but notlimited to, those which infer that Cardiac Science Corporation's futurerevenue and profits may grow as a result of sales of defibrillation products.These statements and their underlying assumptions involve a number of risksand uncertainties and are not guarantees of future performance.